Vivo Capital LLC Buys 737,298 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Vivo Capital LLC grew its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 49.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,234,566 shares of the company's stock after purchasing an additional 737,298 shares during the quarter. Corvus Pharmaceuticals makes up approximately 1.3% of Vivo Capital LLC's portfolio, making the stock its 17th largest holding. Vivo Capital LLC owned 3.48% of Corvus Pharmaceuticals worth $11,955,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. State Street Corp lifted its position in Corvus Pharmaceuticals by 48.2% in the third quarter. State Street Corp now owns 178,246 shares of the company's stock worth $941,000 after purchasing an additional 57,943 shares during the period. Jane Street Group LLC bought a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth about $265,000. XTX Topco Ltd acquired a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at about $74,000. Geode Capital Management LLC increased its stake in Corvus Pharmaceuticals by 22.4% in the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company's stock valued at $2,974,000 after acquiring an additional 102,869 shares during the period. Finally, Virtu Financial LLC acquired a new position in Corvus Pharmaceuticals in the third quarter worth about $83,000. Institutional investors own 46.64% of the company's stock.

Corvus Pharmaceuticals Price Performance

NASDAQ:CRVS traded down $0.03 during trading hours on Friday, reaching $3.63. 685,657 shares of the stock were exchanged, compared to its average volume of 639,602. Corvus Pharmaceuticals, Inc. has a twelve month low of $1.43 and a twelve month high of $10.00. The stock has a market cap of $247.33 million, a PE ratio of -3.90 and a beta of 0.71. The firm has a 50 day moving average of $3.73 and a 200 day moving average of $5.72.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.06). Equities research analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on CRVS shares. Oppenheimer reaffirmed an "outperform" rating and issued a $15.00 price target (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. HC Wainwright restated a "buy" rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $15.67.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.